30.06
-0.16 (-0.53%)
-0.16 (-0.53%)
Upgrade to Real-Time
Afterhours
Best deals to access real time data! |
|
CHART Trader
Monthly Subscription
for only
|
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Halozyme Therapeutics Incorporated | HALO | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| -0.16 | -0.53% | 30.06 | 17:12:30 |
| Close Price | Low Price | High Price | Open Price | Previous Close |
|---|---|---|---|---|
| 30.06 | 29.885 | 30.85 | 30.39 | 30.22 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 29.80 | 30.16 | 0.36 | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 12,922 | 1,953,677 | $ 30.32 | $ 59,238,865 | 1,183,951 | 12.71 - 30.88 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:34:18 | priorref | 15,555 | $ 30.06 | USD |
Halozyme Therapeutics Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 4.12B | 137.03M | 121.99M | $ 195.99M | $ -21.44M | -0.50 | -192.10 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | -115.83k | 8.30% |
Halozyme Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical HALO Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 28.44 | 30.88 | 28.175 | 29.45 | 1,710,308 | 1.62 | 5.7% |
| 1 Month | 26.65 | 30.88 | 25.17 | 27.79 | 1,092,394 | 3.41 | 12.8% |
| 3 Months | 27.17 | 30.88 | 25.17 | 27.92 | 1,010,837 | 2.89 | 10.64% |
| 6 Months | 19.42 | 30.88 | 19.36 | 26.04 | 1,210,561 | 10.64 | 54.79% |
| 1 Year | 15.36 | 30.88 | 12.71 | 21.58 | 1,453,392 | 14.70 | 95.7% |
| 3 Years | 17.82 | 30.88 | 12.71 | 19.39 | 1,059,842 | 12.24 | 68.69% |
| 5 Years | 13.95 | 30.88 | 6.96 | 15.93 | 1,197,091 | 16.11 | 115.48% |
Halozyme Therapeutics Description
| Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally. |
